# Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

> **NCT02772107** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 132 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** first-line chemotherapy
- **RADIATION:** Prophylactic cranial irradiation
- **RADIATION:** thoracic radiotherapy

## Key facts

- **NCT ID:** NCT02772107
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2017-06
- **Final completion:** 2018-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2016-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772107, "Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02772107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*